PE20060727A1 - Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) - Google Patents
Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)Info
- Publication number
- PE20060727A1 PE20060727A1 PE2005001280A PE2005001280A PE20060727A1 PE 20060727 A1 PE20060727 A1 PE 20060727A1 PE 2005001280 A PE2005001280 A PE 2005001280A PE 2005001280 A PE2005001280 A PE 2005001280A PE 20060727 A1 PE20060727 A1 PE 20060727A1
- Authority
- PE
- Peru
- Prior art keywords
- vegf
- methyl
- growth factor
- receptor kinase
- anthranylamidopyridines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE X ES C, N; W ES H, FLUOR; A, E Y Q SON C, N; R1 ES ARILO, HETEROARILO OPCIONALMENTE SUSTITUIDO; R2 Y R3 SON ALQUILO(C1-C12) OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: 2-{[2-(3,3-DIMETIL-UREIDO)-PIRIDIN-4-ILMETIL]-AMINO}-N-(2-METIL-2H-INDAZOL-6-IL)-BENZAMIDA, 2-({2-[3-(2-METOXI-ETIL)-3-METIL-UREIDO]-PIRIDIN-4-ILMETIL}-AMINO)-N-(2-METIL-2H-INDAZOL-6-IL)-BENZAMIDA, 2-{[2-(3,3-DIMETIL-UREIDO)-PIRIDIN-4-ILMETIL]-AMINO}-N-(4-FLUORO-2-METIL-2H-INDAZOL-6-IL)-BENZAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS INHIBEN LA QUINASA RECEPTORA DEL FACTOR DE CRECIMIENTO VASCULAR ENDOTELIAL (VEGF) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO ENDOMETRIOSIS, LEUCEMIA, ARTRITIS REUMATOIDE
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04090419A EP1655295A1 (en) | 2004-11-03 | 2004-11-03 | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060727A1 true PE20060727A1 (es) | 2006-08-04 |
Family
ID=34928840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005001280A PE20060727A1 (es) | 2004-11-03 | 2005-11-02 | Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) |
Country Status (23)
Country | Link |
---|---|
US (2) | US7902229B2 (es) |
EP (2) | EP1655295A1 (es) |
JP (1) | JP4988584B2 (es) |
KR (1) | KR101280809B1 (es) |
CN (1) | CN101052634B (es) |
AR (1) | AR051413A1 (es) |
AU (1) | AU2005300736B2 (es) |
BR (1) | BRPI0517963A2 (es) |
CA (1) | CA2586271C (es) |
GT (1) | GT200500316A (es) |
HK (1) | HK1109403A1 (es) |
IL (1) | IL182399A0 (es) |
MX (1) | MX2007005339A (es) |
MY (1) | MY147642A (es) |
NO (1) | NO20072804L (es) |
PA (1) | PA8651301A1 (es) |
PE (1) | PE20060727A1 (es) |
RU (1) | RU2415850C2 (es) |
SV (1) | SV2006002288A (es) |
TW (1) | TWI409066B (es) |
UY (1) | UY29186A1 (es) |
WO (1) | WO2006048251A1 (es) |
ZA (1) | ZA200705009B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) * | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
RU2008126228A (ru) | 2005-11-30 | 2010-01-10 | Астеллас Фарма Инк. (Jp) | 2-аминобензамидное производное |
EP2008658A1 (en) * | 2007-06-28 | 2008-12-31 | Bayer Schering Pharma Aktiengesellschaft | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives |
ES2445517T3 (es) * | 2008-08-27 | 2014-03-03 | Leo Pharma A/S | Derivados de piridina como inhibidores de receptor VEGFR-2 y proteína tirosina cinasa |
EP2712862A1 (en) * | 2012-09-28 | 2014-04-02 | Splicos | New anti-invasive compounds |
CN103396361B (zh) * | 2013-07-24 | 2016-05-04 | 中国人民解放军第二军医大学 | 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用 |
CN103739550B (zh) * | 2014-01-02 | 2016-06-01 | 中国药科大学 | 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用 |
CN103936719A (zh) * | 2014-05-14 | 2014-07-23 | 中国药科大学 | 苯并咪唑类衍生物制备方法及用途 |
DK3174868T3 (da) | 2014-08-01 | 2021-11-08 | Nuevolution As | Forbindelser, der er aktive mod bromodomæner |
PE20200008A1 (es) | 2017-03-30 | 2020-01-06 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1 |
CN109942544B (zh) * | 2017-12-21 | 2021-06-11 | 中国科学院合肥物质科学研究院 | 一类新型吲唑类衍生物激酶抑制剂 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3226394A (en) | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
JPS5744672B2 (es) | 1974-05-24 | 1982-09-22 | ||
DE2652144A1 (de) | 1976-11-16 | 1978-05-18 | Merck Patent Gmbh | Neue chinazolindione |
EP0117462A3 (en) | 1983-02-28 | 1986-08-20 | American Cyanamid Company | N-(2-4-(1h-imidazol-1-yl)alkyl)arylamides |
US4568687A (en) | 1983-02-28 | 1986-02-04 | American Cyanamid Company | N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions |
FR2689508B1 (fr) | 1992-04-01 | 1994-06-17 | Fournier Ind & Sante | Derives de l'imidazole, leur procede de preparation et leur application en therapeutique. |
AU6910994A (en) | 1993-05-14 | 1994-12-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity |
EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
CA2155662A1 (en) | 1993-12-27 | 1995-07-06 | Fumihiro Ozaki | Anthranilic acid derivative |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
DE19910396C2 (de) | 1999-03-03 | 2001-12-13 | Schering Ag | Anthranilsäureamide und deren Verwendung als Arzneimittel |
WO2000039118A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Aromatic amides |
DE50000678D1 (de) * | 1999-02-22 | 2002-11-28 | Gernot Treusch | Therapeutisch wirksames stoffgemisch enthaltend s-acetylglutathion und aciclovir |
GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
DE10023485A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
CA2430951A1 (en) | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
IL158783A0 (en) | 2001-05-08 | 2004-05-12 | Schering Ag | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
JP2004528378A (ja) * | 2001-05-08 | 2004-09-16 | シエーリング アクチエンゲゼルシャフト | N−オキシドアントラニルアミド誘導体と医薬製剤としての利用 |
DE50206476D1 (de) * | 2001-05-08 | 2006-05-24 | Schering Ag | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
GB0126902D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
WO2003048081A2 (en) | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
JP2003250770A (ja) * | 2002-02-28 | 2003-09-09 | Omron Corp | 電子血圧計 |
DE10228090A1 (de) | 2002-06-19 | 2004-01-15 | Schering Ag | Ausgewählte Anthranylamidpyridinamide und deren Verwendung als Arzneimittel |
US20040039019A1 (en) | 2002-06-19 | 2004-02-26 | Schering Ag | Selected anthranilaminde pyridinamides and their use as pharmaceutical agents |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7148357B2 (en) * | 2002-07-31 | 2006-12-12 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
US7517894B2 (en) | 2002-07-31 | 2009-04-14 | Bayer Schering Pharma Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
KR20050026535A (ko) * | 2002-07-31 | 2005-03-15 | 쉐링 악티엔게젤샤프트 | Vegfr-2 및 vegfr-3 억제성 안트라닐아미도피리딘 |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
-
2004
- 2004-11-03 EP EP04090419A patent/EP1655295A1/en not_active Withdrawn
-
2005
- 2005-10-26 TW TW094137517A patent/TWI409066B/zh not_active IP Right Cessation
- 2005-10-27 MY MYPI20055069A patent/MY147642A/en unknown
- 2005-10-31 BR BRPI0517963-7A patent/BRPI0517963A2/pt not_active IP Right Cessation
- 2005-10-31 EP EP05802073A patent/EP1807413A1/en not_active Withdrawn
- 2005-10-31 JP JP2007538359A patent/JP4988584B2/ja not_active Expired - Fee Related
- 2005-10-31 MX MX2007005339A patent/MX2007005339A/es active IP Right Grant
- 2005-10-31 UY UY29186A patent/UY29186A1/es not_active Application Discontinuation
- 2005-10-31 GT GT200500316A patent/GT200500316A/es unknown
- 2005-10-31 AU AU2005300736A patent/AU2005300736B2/en not_active Ceased
- 2005-10-31 RU RU2007120692/04A patent/RU2415850C2/ru not_active IP Right Cessation
- 2005-10-31 CN CN200580037857XA patent/CN101052634B/zh not_active Expired - Fee Related
- 2005-10-31 KR KR1020077012382A patent/KR101280809B1/ko not_active IP Right Cessation
- 2005-10-31 CA CA2586271A patent/CA2586271C/en not_active Expired - Fee Related
- 2005-10-31 WO PCT/EP2005/011712 patent/WO2006048251A1/en active Application Filing
- 2005-11-02 PA PA20058651301A patent/PA8651301A1/es unknown
- 2005-11-02 PE PE2005001280A patent/PE20060727A1/es not_active Application Discontinuation
- 2005-11-02 AR ARP050104581A patent/AR051413A1/es not_active Application Discontinuation
- 2005-11-03 US US11/265,517 patent/US7902229B2/en not_active Expired - Fee Related
- 2005-11-03 SV SV2005002288A patent/SV2006002288A/es unknown
-
2007
- 2007-04-10 IL IL182399A patent/IL182399A0/en unknown
- 2007-06-01 ZA ZA2007/05009A patent/ZA200705009B/en unknown
- 2007-06-01 NO NO20072804A patent/NO20072804L/no not_active Application Discontinuation
-
2008
- 2008-03-28 HK HK08103481.2A patent/HK1109403A1/xx not_active IP Right Cessation
-
2011
- 2011-02-02 US US13/019,530 patent/US20110124680A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110124680A1 (en) | 2011-05-26 |
RU2007120692A (ru) | 2008-12-10 |
WO2006048251A1 (en) | 2006-05-11 |
UY29186A1 (es) | 2006-05-31 |
SV2006002288A (es) | 2006-06-26 |
TWI409066B (zh) | 2013-09-21 |
ZA200705009B (en) | 2014-12-23 |
KR20070085610A (ko) | 2007-08-27 |
EP1807413A1 (en) | 2007-07-18 |
CA2586271C (en) | 2013-08-06 |
RU2415850C2 (ru) | 2011-04-10 |
BRPI0517963A2 (pt) | 2009-03-24 |
CN101052634B (zh) | 2011-05-18 |
KR101280809B1 (ko) | 2013-07-02 |
MX2007005339A (es) | 2007-08-17 |
US7902229B2 (en) | 2011-03-08 |
AU2005300736A1 (en) | 2006-05-11 |
PA8651301A1 (es) | 2006-07-03 |
JP4988584B2 (ja) | 2012-08-01 |
NO20072804L (no) | 2007-08-03 |
TW200621714A (en) | 2006-07-01 |
AU2005300736B2 (en) | 2012-01-19 |
AR051413A1 (es) | 2007-01-10 |
CN101052634A (zh) | 2007-10-10 |
US20060116380A1 (en) | 2006-06-01 |
EP1655295A1 (en) | 2006-05-10 |
GT200500316A (es) | 2006-06-06 |
JP2008518894A (ja) | 2008-06-05 |
CA2586271A1 (en) | 2006-05-11 |
IL182399A0 (en) | 2007-07-24 |
HK1109403A1 (en) | 2008-06-06 |
MY147642A (en) | 2012-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20060727A1 (es) | Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) | |
PE20080538A1 (es) | Derivado heterociclico fusionado y su uso | |
PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20090215A1 (es) | Compuestos derivados de imidazopiridazinas como inhibidores de cinasa | |
PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
PE20121431A1 (es) | Derivados de pirimidina como inhbidores de la enzima cinasa ptk2 | |
PE20080768A1 (es) | Compuestos de isoindolina 5-sustituidos | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20140609A1 (es) | Diazacarbazoles y metodos de uso | |
CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
PE20081659A1 (es) | Agonistas de gpcr | |
PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
PE20060079A1 (es) | DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5 | |
PE20120081A1 (es) | Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton | |
PE20090480A1 (es) | Derivados de lactama tetraciclicos | |
PE20120229A1 (es) | Compuestos heterociclicos como inhibidores de proteasa aspartica | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
PE20121510A1 (es) | Isoquinolinonas y quinazolinonas sustituidas | |
PE20130188A1 (es) | Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
PE20110409A1 (es) | Compuestos heterociclicos antiviricos | |
PE20050767A1 (es) | Amino-benzazoles como inhibidores del receptor p2y1 | |
PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
PE20091324A1 (es) | Compuestos espiro como antagonistas del receptor npy y5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |